bevacizumab,sorafenib
roche,bayer
[]
hcc from asco gi23: localized therapy and sorafenib improving survival -resectable: tace and sorafenib imporved os -unresectable: nrg study: sbrt and sorafenib improved os. unsure how this is in comparison to ate and bev #gi23
#GIONC. GI Medical Oncologist & Assistant Professor @WilmotCancer. @UR_Med. All opinions are mine.